Lawsuits filed in New Jersey are part of hundreds of complaints against UnitedHealthcare, PBMs, and pharmaceutical giants ...

Few companies have broken into the public’s consciousness as thoroughly as Novo Nordisk has over the past ... took steps to minimize demand from new patients and increase the likelihood there ...

Right now, Novo stock is trading at a forward price-to-earnings (P/E) multiple of 22.5 -- its lowest level in well over a year. I think now is a terrific opportunity to scoop up shares of Novo on the ...

Novo Nordisk’s takeover of Catalent and the Danish firm’s push to launch a new generation of drugs could boost the importance of GLP agonists in 2025, Barclays analysts said ...